Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy (Q37871625)

24 August 2017

1 reference

title

Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy (English)

1 reference

24 August 2017

0 references

0 references

0 references

0 references

1 reference

24 August 2017

S Danese

1 reference

24 August 2017

W Reinisch

series ordinal

1 reference

24 August 2017

language of work or name

English

0 references

publication date

3 May 2011

1 reference

Alimentary Pharmacology & Therapeutics

24 August 2017

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

1-10

1 reference

Biological therapies for inflammatory bowel diseases

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Review article: smoking cessation as primary therapy to modify the course of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04679.X

10.1111/J.1365-2036.2011.04679.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference